Photocure $PHO.OL stock rally ahead of Q4 report - One to watch
Cập nhật
Photocure stock reacted with a heavy (overdone?) correction after the Q3 report, but has recovered nicely in later weeks.
As mentioned in an earlier TradingView analysis (https://www.tradingview.com/chart/PHOO/wtgi4lhc-photocure-Trading-ideas/), NOK 36 and downwards presented a very good buying opportunity, which culminated when the correction bottomed at NOK 32,5 which was a very solid resistance upwards for a long time.
Entry at these levels should probably be done with a keen eye on risk management and new investors may want to wait for the soon to come Q4 2018 report before making a move, but the long term uptrend looks promising, and at a valuation of only 113 million USD this Norwegian microcap could go a long way yet.
Quoting Pengana capital about their position in Photocure:
"Photocure has a current market capitalisation of USD $130 million and we estimate 2018 revenue of USD $25 million which is small compared to the potential US market opportunity valued at $1.3 billion. The company has also had great success in selling its product in Europe, with an 80% penetration in bladder surgery procedures in Scandinavia followed by 30% in Germany."
https://www.raskmedia.com.au/2018/11/20/heres-why-we-own-photocure-asa-phs-stock/
As mentioned in an earlier TradingView analysis (https://www.tradingview.com/chart/PHOO/wtgi4lhc-photocure-Trading-ideas/), NOK 36 and downwards presented a very good buying opportunity, which culminated when the correction bottomed at NOK 32,5 which was a very solid resistance upwards for a long time.
Entry at these levels should probably be done with a keen eye on risk management and new investors may want to wait for the soon to come Q4 2018 report before making a move, but the long term uptrend looks promising, and at a valuation of only 113 million USD this Norwegian microcap could go a long way yet.
Quoting Pengana capital about their position in Photocure:
"Photocure has a current market capitalisation of USD $130 million and we estimate 2018 revenue of USD $25 million which is small compared to the potential US market opportunity valued at $1.3 billion. The company has also had great success in selling its product in Europe, with an 80% penetration in bladder surgery procedures in Scandinavia followed by 30% in Germany."
https://www.raskmedia.com.au/2018/11/20/heres-why-we-own-photocure-asa-phs-stock/
Đóng lệnh: đạt mục tiêu
As was somewhat expected, by the traditional habit of biotech selling the news the stock reacted downwards.
Thông báo miễn trừ trách nhiệm
Thông tin và ấn phẩm không có nghĩa là và không cấu thành, tài chính, đầu tư, kinh doanh, hoặc các loại lời khuyên hoặc khuyến nghị khác được cung cấp hoặc xác nhận bởi TradingView. Đọc thêm trong Điều khoản sử dụng.